Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Single-Agent OSI-7904L in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed First-Line Therapy

NCT00116909 is registered in ClinicalTrials.gov with OSI Pharmaceuticals as lead sponsor.

NCT NCT00116909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Single-Agent OSI-7904L in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed First-Line Therapy
Lead sponsor
OSI Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2004
Completion date
August 31, 2005
Enrollment
85
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

locally recurrent or metastatic cancer of the head and neck, must have failed first-line therapy